Recurrent hemoptysis after laryngectomy-acquired hemophilia induced by laryngeal cancer surgery and chemoradiotherapy: A case report

Figure 1 Dynamic changes in activated partial thromboplastin time levels throughout the patient’s clinical course. The line graph illustrates the trends in activated partial thromboplastin time (APTT) levels during the patient’s disease progression. The green shaded area denotes the normal reference range, and red dots indicate abnormal values. Key clinical milestones are annotated: Preoperative status (January 7, 2019), initiation of chemoradiotherapy (May 6, 2019), and immunosuppressive therapy for acquired hemophilia A (AHA) beginning on March 8, 2020 (Cyclophosphamide + Prednisone). Subsequent regimen adjustments included: Cyclophosphamide + Prednisone (March 30, 2020), Azathioprine + Prednisone (April 29, 2020), discontinuation of Prednisone (May 27, 2020; monotherapy with Azathioprine), and cessation of Azathioprine (December 1, 2021). Notably, APTT levels stabilized within the normal range following the initiation of AHA-directed immunosuppressive therapy. APTT: Activated partial thromboplastin time.